HC Wainwright Reaffirms Buy Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

HC Wainwright reaffirmed their buy rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a report released on Monday morning,Benzinga reports. They currently have a $10.00 price target on the stock.

Several other research analysts also recently weighed in on ZNTL. Wedbush reissued a “neutral” rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. UBS Group dropped their target price on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Finally, Wells Fargo & Company dropped their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Zentalis Pharmaceuticals has an average rating of “Hold” and a consensus price target of $8.24.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL opened at $1.89 on Monday. The firm’s 50 day moving average is $2.19 and its 200-day moving average is $2.94. The stock has a market capitalization of $134.69 million, a P/E ratio of -0.76 and a beta of 1.75. Zentalis Pharmaceuticals has a 12-month low of $1.61 and a 12-month high of $16.27.

Insider Buying and Selling

In related news, Director Jan Skvarka purchased 60,000 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was acquired at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the acquisition, the director now owns 149,551 shares in the company, valued at $257,227.72. This trade represents a 67.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Ingmar Bruns purchased 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 6th. The shares were bought at an average price of $2.28 per share, with a total value of $45,600.00. Following the completion of the acquisition, the insider now owns 36,629 shares of the company’s stock, valued at $83,514.12. This trade represents a 120.27 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Zentalis Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Erste Asset Management GmbH acquired a new stake in Zentalis Pharmaceuticals in the third quarter valued at approximately $37,000. Paloma Partners Management Co acquired a new stake in Zentalis Pharmaceuticals in the third quarter valued at approximately $37,000. Corton Capital Inc. acquired a new stake in Zentalis Pharmaceuticals in the fourth quarter valued at approximately $32,000. Captrust Financial Advisors acquired a new stake in Zentalis Pharmaceuticals in the fourth quarter valued at approximately $33,000. Finally, Aigen Investment Management LP acquired a new stake in Zentalis Pharmaceuticals in the third quarter valued at approximately $41,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.